tiprankstipranks
Advertisement
Advertisement

PPBT Stock Latest News

Purple Biotech Unveils August 2026 Corporate Update on Tri-Specific Immuno-Oncology Platform
Company AnnouncementsPurple Biotech Unveils August 2026 Corporate Update on Tri-Specific Immuno-Oncology Platform
3d ago
6K
PPBT
Purple Biotech price target lowered to $17 from $30 at H.C. Wainwright
PremiumThe Fly
Purple Biotech price target lowered to $17 from $30 at H.C. Wainwright
6d ago
PPBT
Purple Biotech Posts Q2 2026 Results as IM1240 Preclinical Data Strengthen Immunotherapy Platform
PremiumCompany Announcements
Purple Biotech Posts Q2 2026 Results as IM1240 Preclinical Data Strengthen Immunotherapy Platform
7d ago
6K
PPBT
Purple Biotech Sets September 8, 2026 AGM to Reshape Board Roles and Compensation Policy
PremiumCompany Announcements
Purple Biotech Sets September 8, 2026 AGM to Reshape Board Roles and Compensation Policy
15d ago
6K
PPBT
Purple Biotech Updates Investors on CAPTN-3 Platform and Pipeline as IM1240 Nears 2027 Clinic Entry
PremiumCompany Announcements
Purple Biotech Updates Investors on CAPTN-3 Platform and Pipeline as IM1240 Nears 2027 Clinic Entry
2M ago
6K
PPBT
Purple Biotech presents new IM1240 data at EACR
PremiumThe FlyPurple Biotech presents new IM1240 data at EACR
2M ago
PPBT
Purple Biotech Unveils IM1240 Preclinical Data at EACR 2026, Validating CAPTN-3 Immunotherapy Platform
Premium
Company Announcements
Purple Biotech Unveils IM1240 Preclinical Data at EACR 2026, Validating CAPTN-3 Immunotherapy Platform
2M ago
6K
PPBT
Purple Biotech files $200M mixed securities shelf
Premium
The Fly
Purple Biotech files $200M mixed securities shelf
3M ago
PPBT
Purple Biotech Q1 2026 Results Highlight CAPTN-3 Pivot and IM1240 Preclinical Momentum
PremiumCompany Announcements
Purple Biotech Q1 2026 Results Highlight CAPTN-3 Pivot and IM1240 Preclinical Momentum
3M ago
6K
PPBT
Purple Biotech Unveils Promising IM1240 Preclinical Data From CAPTN-3 Immunotherapy Platform
PremiumCompany Announcements
Purple Biotech Unveils Promising IM1240 Preclinical Data From CAPTN-3 Immunotherapy Platform
4M ago
6K
PPBT
Purple Biotech reports IM1240 demonstrates potent anti-tumor activity
PremiumThe Fly
Purple Biotech reports IM1240 demonstrates potent anti-tumor activity
4M ago
PPBT
Purple Biotech Forms Scientific Advisory Board to Drive CAPTN-3 Tri-Specific Antibody Platform
PremiumCompany Announcements
Purple Biotech Forms Scientific Advisory Board to Drive CAPTN-3 Tri-Specific Antibody Platform
4M ago
6K
PPBT
Purple Biotech Taps Converge Bio’s AI to Turbocharge Tri-Specific Antibody Platform
PremiumCompany AnnouncementsPurple Biotech Taps Converge Bio’s AI to Turbocharge Tri-Specific Antibody Platform
5M ago
6K
PPBT
Purple Biotech announces collaboration with Converge Bio
Premium
The Fly
Purple Biotech announces collaboration with Converge Bio
5M ago
PPBT
Purple Biotech Is Building What Could Be the Next Generation of Cancer Immunotherapy (NASDAQ: PPBT)
Premium
TipRanks Newswire
Purple Biotech Is Building What Could Be the Next Generation of Cancer Immunotherapy (NASDAQ: PPBT)
5M ago
CODX
PPBT
Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns
PremiumCompany Announcements
Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns
5M ago
PPBT
Purple Biotech Updates March 2026 Corporate Outlook and Pipeline Milestones
PremiumCompany Announcements
Purple Biotech Updates March 2026 Corporate Outlook and Pipeline Milestones
5M ago
6K
PPBT
Purple Biotech regains compliance with Nasdaq
PremiumThe Fly
Purple Biotech regains compliance with Nasdaq
5M ago
PPBT
Purple Biotech Regains Nasdaq Compliance on Minimum Bid Price
PremiumCompany Announcements
Purple Biotech Regains Nasdaq Compliance on Minimum Bid Price
5M ago
6K
PPBT
Purple Biotech price target lowered to $30 from $34 at H.C. Wainwright
PremiumThe FlyPurple Biotech price target lowered to $30 from $34 at H.C. Wainwright
5M ago
PPBT
Purple Biotech Posts 2025 Loss, Doubles Down on CAPTN-3 Immunotherapy Platform
Premium
Company Announcements
Purple Biotech Posts 2025 Loss, Doubles Down on CAPTN-3 Immunotherapy Platform
5M ago
6K
PPBT
Purple Biotech CEO Gil Efron to step down in August
Premium
The Fly
Purple Biotech CEO Gil Efron to step down in August
5M ago
PPBT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >